Skip to content

SOHO announces exclusive MDS, AML session on September 8 in Houston; register now
Dr. Raheel Iftikhar weighs in on AI in blood cancers
Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL
Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification
Don’t miss SOHO 2026 poster walks

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Saad Usmani, MD

Cellular Therapy

Saad Usmani, MD

Leukemia

Saad Usmani, MD

Lymphoma

Saad Usmani, MD

Multiple Myeloma

Saad Usmani, MD

Myelodysplastic Syndromes

Saad Usmani, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

April 12, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Saad Usmani, MD

Saad Usmani, MD

by sohonews
January 31, 2025
0 Comments
Less than a minute
649 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Exclusive_Session_SOHO_26

SOHO 2026, Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, News, Society Updates

SOHO announces exclusive MDS, AML session on September 8

April 10, 2026

Microscope in AI virtual pattern

SOHO 2025, Ambassador Program, Lymphoma, Aggressive B-Cell Lymphomas, Multiple Myeloma, News

Dr. Raheel Iftikhar weighs in on AI in blood

April 9, 2026

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Lymphoma, Indolent B-Cell Lymphomas

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

April 8, 2026

SOHO Asia 2026, Leukemia, Acute Myeloid Leukemia, News, Video Interviews

Dr. Feng-Ming Tien on immune landscapes and the future

April 8, 2026

poster_walks_960x520

SOHO 2026, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, News, Society Updates

Don’t miss SOHO 2026 poster walks

April 7, 2026

Japanese flag

Cellular Therapy, Multiple Myeloma, News

Japan’s PMDA clears phase 3 trial of eque-cel in

April 6, 2026

Top Categories

Cellular Therapy

65

Leukemia

102

Lymphoma

111

Multiple Myeloma

87

Myelodysplastic Syndromes

34

Myeloproliferative Neoplasms

21

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Saad Usmani, MD

Cellular Therapy

Saad Usmani, MD

Leukemia

Saad Usmani, MD

Lymphoma

Saad Usmani, MD

Multiple Myeloma

Saad Usmani, MD

Myelodysplastic Syndromes

Saad Usmani, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Exclusive_Session_SOHO_26

SOHO announces exclusive MDS, AML session on September 8 in Houston; register now

Microscope in AI virtual pattern

Dr. Raheel Iftikhar weighs in on AI in blood cancers

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.